24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Alzheimers Disease and other Cognitive Disorders
Resources
Basic Information
Introduction & Causes of Cognitive DisordersDementiaAlzheimer's DiseaseOther Cognitive DisordersDementia Coping Skills & Behavior ManagementTraumatic Brain Injury (TBI)Conclusion and Resources
More InformationLatest News
Targeting 9 Risk Factors Could Prevent 1 in 3 Dementia Cases: StudyAAIC: Rx + Training Shows Benefit in Advanced Alzheimer'sAAIC: Alzheimer Biomarkers Up With Sleep Disordered BreathingDozens of Potential Alzheimer's Meds in the PipelineSpecial Training Plus Medication Might Help People With Advanced Alzheimer'sOne Social Hour a Week Can Help Someone With DementiaSleep Problems: An Early Warning Sign of Alzheimer's?Severe Head Injury May Raise Dementia Risk Years LaterPPIs Not Found to Raise Risk of Alzheimer's DiseasePopular Heartburn Meds Don't Raise Alzheimer's Risk: StudyLifestyle Changes Might Prevent or Slow DementiaSevere Headaches Plague Vets With Traumatic Brain InjuriesSticky Brain 'Plaques' Implicated in Alzheimer's Again'Making the Best of It': Families Face the Heavy Burden of Alzheimer'sCognitive Decline Linked to Visual Field VariabilityAlzheimer's Deaths Jump 55 Percent: CDCLife Expectancy Slighter Shorter With Parkinson's, DementiaLow Body Mass Index Not Risk Factor for Alzheimer's DiseaseThin People Not More Prone to Alzheimer's, Study FindsWives, Daughters Shoulder Most of Alzheimer's Care BurdenGene Mutation May Speed Alzheimer's DeclineSilent Seizures May Contribute to Alzheimer's Pathology'Silent' Seizures Tied to Alzheimer's SymptomsPsychiatric Scars of Wartime Brain Injury May Linger for YearsMany Patients With Alzheimer's Disease Discontinue AChEIsMicrovascular Endothelial Dysfunction Can Predict DementiaAntipsychotic Medication Use Can Be Reduced in Dementia PatientsPast Psychiatric Disorders Do Not Raise Risk of Alzheimer's DiseasePast Psychiatric Ills Don't Raise Alzheimer's Risk: StudyXanax, Valium May Boost Pneumonia Risk in Alzheimer's PatientsSGA Prescribing Higher for Veterans With PTSD/DementiaDrug Tied to Dementia Risk Overprescribed to Seniors: StudyProton Pump Inhibitor Use Ups Pneumonia Risk in DementiaVitamin E, Selenium Supplements Won't Curb Men's Dementia RiskDizzy Spells in Middle-Age Tied to Dementia Risk LaterFive Million American Seniors Now Living With Alzheimer'sStudy: Gene Test Needed Before Using Alzheimer's Drug 'Off-Label'Annual Death Toll From Alzheimer's Nearly Doubles in 15 YearsImmune Disorders Such as MS, Psoriasis May Be Tied to Dementia RiskIs Need for More Sleep a Sign of Pending Dementia?Unhealthy in Middle Age, Dementia in Old Age?HRT Won't Lower Women's Alzheimer's Risk, Study FindsReview Links Albuminuria to Cognitive Impairment, DementiaCan Air Pollution Heighten Alzheimer's Risk?Bilingual People May Have an Edge Against Alzheimer'sBusy Minds May Be Better at Fighting DementiaDementia May Be Exacerbated by Hospital-Related DeliriumLink Seen Between Concussions and Alzheimer'sContinuing Warfarin Protective After Diagnosis of DementiaDoes Living Near Major Roads Boost Dementia Risk?
Questions and AnswersLinks
Related Topics

Study: Gene Test Needed Before Using Alzheimer's Drug 'Off-Label'

HealthDay News
by -- Robert Preidt
Updated: Mar 7th 2017

new article illustration

TUESDAY, March 7, 2017 (HealthDay News) -- A drug used to treat Alzheimer's disease should not be prescribed to people with milder mental impairment without first giving them a genetic test, a new study urges.

The drug is donepezil (brand name: Aricept).

Donepezil could speed mental decline in someone with mild cognitive impairment who has a specific genetic variation, according to Sophie Sokolow, an associate professor at the UCLA School of Nursing.

She and her colleagues found that patients with the K-variant of the butyrylcholinesterase (BChE) gene who took donepezil deteriorated faster than those who took a placebo.

Donepezil is approved in the United States to treat Alzheimer's disease but not mild cognitive impairment -- the stage between normal age-related decline and dementia. However, doctors often prescribe it "off-label" for patients with mild cognitive impairment, the study authors said.

For this study, the researchers examined data from a U.S. government-funded study published in 2005 that assessed donepezil as a possible treatment for mild cognitive impairment.

The findings reinforce the importance of physicians discussing the possible benefits and risks of donepezil with their patients, the researchers said in a university news release.

The study was published recently in the Journal of Alzheimer's Disease. Funding was provide by the U.S. National Institute on Aging.

More information

The Alzheimer's Association has more on mild cognitive impairment.